Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies | Angalakuditi et al. Health and Quality of Life Outcomes 2010 8 131 http www.hqlo.eom content 8 1 131 HEALTH AND QUALITY of life outcomes RESEARCH Open Access Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies K lpillilp ArcrìLìI idifi 1 Rita p Riaitiapt2 Rira p I laviaCt ichaol p rvi r ìp 3 I arc ilptri m1 Mallik AiiyalakLiuiu Rita F Seifert Risa P Hayes Iviiciiael P O Leary Lais Viktrup Abstract Background To assess the measurement properties of the Benign Prostatic Hyperplasia Impact Index BII for use in men with Lower Urinary Tract Symptoms LUTS secondary to Benign Prostatic Hyperplasia BPH treated with tadalafil. Methods Data from a dose-titration Study 1 and a dose-finding placebo-controlled Study 2 tadalafil studies of men 45 years of age or older with moderate to severe LUTS N 281 N 1053 were included in this post-hoc analysis. Measures included the BII International Prostate Symptom Score IPSS IPSS Quality of Life Index IPSS-QoL LUTS Global Assessment Question uroflowmetry measure peak flow rate Qmax and postvoid residual volume PVR . Spearman rank and Pearson correlation coefficients were computed between the BII score and the other measures at each visit. Wilcoxin two-sample tests t-tests and general linear modeling compared BII scores of subjects with global ratings of improvement versus no improvement and subjects taking tadalafil versus placebo. Effect size standardized response mean and Guyatt s responsiveness statistic were calculated for BII and IPSS change scores. Results There were high correlations between BII and IPSS IPSS-QoL and low correlations between BII and Qmax PVR at each visit. There were significant differences in BII at the End-of-Study Visit between subjects reporting improvement versus subjects reporting no improvement Studies 1 and 2 P .0001 and subjects taking tadalafil versus subjects taking placebo Study 1 P .0045 Study 2 P .0064 . The BII and IPSS were both responsive to change. .
